Literature DB >> 3823444

Adverse reactions to xenon-enhanced CT cerebral blood flow determination.

R E Latchaw, H Yonas, S L Pentheny, D Gur.   

Abstract

Fourteen institutions performed 1,830 computed tomographic (CT) cerebral blood flow (CBF) examinations with 32% inhaled stable xenon. Respiratory rate delay greater than 10 seconds occurred in 3.6% of patients, with 83% of the delays lasting 10-15 seconds. There was no incident of prolonged respiratory difficulty. Headache (0.4%), seizures (0.2%), nausea and vomiting (0.2%), and change in neurologic status (0.1%) were uncommon, and there were no transient ischemic attacks. The CT CBF method with 32% inhaled stable xenon is thus associated with an acceptably low incidence of adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3823444     DOI: 10.1148/radiology.163.1.3823444

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

1.  Cerebral blood flow mapping using stable xenon-enhanced CT in sickle cell cerebrovascular disease.

Authors:  Y Numaguchi; J S Haller; J R Humbert; A E Robinson; W W Lindstrom; L M Gruenauer; J E Carey
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Quantitative tissue blood flow measurement of the liver parenchyma: comparison between xenon CT and perfusion CT.

Authors:  Kazuhiko Hashimoto; Takamichi Murakami; Keizo Dono; Masatoshi Hori; Tonsok Kim; Masayuki Kudo; Shigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Hiroaki Nagano; Koji Umeshita; Hironobu Nakamura; Morito Monden
Journal:  Dig Dis Sci       Date:  2007-02-23       Impact factor: 3.199

3.  Hyperpolarized (129)Xe MRI: a viable functional lung imaging modality?

Authors:  Samuel Patz; F William Hersman; Iga Muradian; Mirko I Hrovat; Iulian C Ruset; Stephen Ketel; Francine Jacobson; George P Topulos; Hiroto Hatabu; James P Butler
Journal:  Eur J Radiol       Date:  2007-09-24       Impact factor: 3.528

4.  Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: a multicenter study.

Authors:  A P Carlson; A M Brown; E Zager; K Uchino; M P Marks; C Robertson; G P Sinson; A Marmarou; H Yonas
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

5.  Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients.

Authors:  Bastiaan Driehuys; Santiago Martinez-Jimenez; Zackary I Cleveland; Gregory M Metz; Denise M Beaver; John C Nouls; S Sivaram Kaushik; Rafael Firszt; Christine Willis; Kevin T Kelly; Jan Wolber; Monica Kraft; H Page McAdams
Journal:  Radiology       Date:  2011-11-04       Impact factor: 11.105

6.  Pulmonary ventilation and perfusion imaging with dual-energy CT.

Authors:  Sven F Thieme; Sandra Hoegl; Konstantin Nikolaou; Juergen Fisahn; Michael Irlbeck; Daniel Maxien; Maximilian F Reiser; Christoph R Becker; Thorsten R C Johnson
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

7.  Imaging evidence and recommendations for traumatic brain injury: advanced neuro- and neurovascular imaging techniques.

Authors:  M Wintermark; P C Sanelli; Y Anzai; A J Tsiouris; C T Whitlow
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-25       Impact factor: 3.825

8.  Physiologic Effects of Xenon in Xenon-CT Cerebral Blood Flow Studies on Comatose Patients.

Authors:  J A Kosty; W A Kofke; E Maloney-Wilensky; S G Frangos; J M Levine; P D Leroux; E L Zager
Journal:  Transl Stroke Res       Date:  2012-06-15       Impact factor: 6.829

Review 9.  X-ray-computed tomography contrast agents.

Authors:  Hrvoje Lusic; Mark W Grinstaff
Journal:  Chem Rev       Date:  2012-12-05       Impact factor: 60.622

10.  Cerebrovascular insufficiency as the criterion for revascularization procedures in selected patients: a correlation study of xenon contrast-enhanced CT and PWI.

Authors:  Gerrit Alexander Schubert; Carolin Weinmann; Marcel Seiz; Lars Gerigk; Christel Weiss; Peter Horn; Claudius Thomé
Journal:  Neurosurg Rev       Date:  2008-09-13       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.